Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M

Esperion Therapeutics, Inc.

FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).
U.S. net product revenue FY24 $115.7M (+48% Y/Y); Q4 $31.6M (+52% Y/Y).
FY24 net loss $51.7M ($0.28/sh) vs $209.2M ($2.03/sh) in 2023; Q4 net loss $21.3M ($0.11/sh).
Announced development of two triple combination products with bempedoic acid.
Strengthened balance sheet: $304.7M from OMERS royalty deal; repaid $210M convertible debt; cash $144.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.